Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report tags : Als save search
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 2.33%
H: 1.69%
C: -6.56%
au8 als treatment
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Published: 2024-02-21 (Crawled : 13:30) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -3.65%
H: 0.0%
C: -5.3%
als positive trial results
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Published: 2023-12-21 (Crawled : 12:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: -34.37%
H: 3.49%
C: -6.8%
au8 label als biomarker treatment extension trial platform
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
Published: 2023-12-14 (Crawled : 14:30) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: 27.94%
H: 6.9%
C: -0.01%
als trial
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Published: 2023-12-04 (Crawled : 21:00) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -30.2%
H: 20.19%
C: 8.65%
report als topline
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
Published: 2023-12-04 (Crawled : 21:00) - prnewswire.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -30.2%
H: 20.19%
C: 8.65%
report als topline
Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls
Published: 2023-09-25 (Crawled : 11:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: 4.51%
H: 9.53%
C: -4.11%
cnm-au8 als treatment trial platform
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
Published: 2023-06-01 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: -2.56%
H: 5.26%
C: 3.29%
business als expected topline trial financial results
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
Published: 2023-05-25 (Crawled : 11:00) - globenewswire.com
APLS G | $47.53 0.04% 0.04% 1.2M
|
Health Technology
|
| O: -0.27%
H: 0.37%
C: -1.38%
als results study phase 2
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
Published: 2022-10-03 (Crawled : 14:20) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
|
| O: -37.14%
H: 21.59%
C: 14.2%
au8 topline als trial platform cnm-au8
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Published: 2022-09-30 (Crawled : 22:00) - globenewswire.com
CLNN S | $0.3492 5.85% 5.53% 1.2M
|
| Email alert
Add to watchlist
report topline als trial results platform
NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
NRSN | $1.435 -5.59% -5.92% 120K
|
|
| O: 52.94%
H: 26.92%
C: -3.85%
als therapeutics positive results biomarkers
Global Biobased and Biodegradable Plastics Market Report 2022: Profiles of 300+ Companies Including Danimer Scientific, Novamont, Mitsubishi Chemicals, Borealis, Dupont, BASF, Clariant and UPM
Published: 2022-03-21 (Crawled : 15:30) - prnewswire.com
LGIQ | $0.0321 16.07% 260K
|
Administrative and Support and ...
|
| O: 1.49%
H: 7.84%
C: -1.47%
NTOIY | $13.64 -4.58% 65K
|
Wholesale Trade
|
| O: -0.88%
H: 0.84%
C: 0.64%
E | $32.51 1.18% 0.0% 170K
|
Energy Minerals
|
| O: 2.12%
H: 1.07%
C: -0.59%
YTEN | $0.252 -7.59% -8.21% 280K
|
Health Technology
|
| O: -0.49%
H: 15.2%
C: 9.31%
als companies report
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
MRNS | $1.38 -2.13% -2.17% 2.6M
|
Health Technology
|
| O: -10.0%
H: 8.22%
C: -2.89%
als financial results report results
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
Published: 2022-03-21 (Crawled : 12:00) - biospace.com/
FUSN | $21.26 0.05% 0.05% 440K
|
Health Technology
|
| O: 4.57%
H: 0.83%
C: -2.42%
DFFN 4 | $6.6 11.68% -34.32% 350K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: -5.07%
als financial results report results
Global 5.1% CAGR of Metal Finishing Chemicals Market Size to Surpass USD 19.12 Bn By 2028: Industry Share, Trends, Forecast Report by ZMR
Published: 2022-03-21 (Crawled : 12:00) - prnewswire.com
CTS S | $43.43 0.77% 0.0% 120K
|
Electronic Technology
|
| O: 0.14%
H: 0.47%
C: -1.49%
als report
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-17 (Crawled : 22:00) - biospace.com/
ANIP S | $65.49 1.41% 1.39% 210K
|
Health Technology
|
| O: -0.43%
H: 6.38%
C: 5.71%
als financial results report results
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022Management to host conference call and webcast at 4:30 pm ET
Published: 2022-03-17 (Crawled : 19:00) - biospace.com/
ELDN | $1.85 -7.03% -7.57% 420K
|
Manufacturing
|
| O: 0.0%
H: 5.78%
C: 4.26%
day als financial results conference report results
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
ACXP | $2.02 -5.16% -5.45% 94K
|
Professional, Scientific, and T...
|
| O: 1.34%
H: 9.55%
C: 0.0%
als report results
Commercial Metals Company Reports Record Second Quarter Fiscal 2022 Results
Published: 2022-03-17 (Crawled : 11:00) - prnewswire.com
CMC | $55.21 -0.13% 0.0% 600K
|
Non-Energy Minerals
|
| O: -0.61%
H: 1.82%
C: -1.25%
als report results commercialization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.